Fortress Biotech (NASDAQ:FBIO – Get Free Report) will likely be issuing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Fortress Biotech to announce earnings of ($0.20) per share and revenue of $18.30 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.
Fortress Biotech (NASDAQ:FBIO – Get Free Report) last posted its quarterly earnings results on Thursday, May 14th. The biopharmaceutical company reported $2.82 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $3.04. Fortress Biotech had a net margin of 193.12% and a return on equity of 109.66%. The business had revenue of $16.04 million for the quarter, compared to the consensus estimate of $16.34 million.
Fortress Biotech Price Performance
Shares of NASDAQ:FBIO opened at $2.75 on Tuesday. The firm has a market cap of $91.35 million, a price-to-earnings ratio of 0.87 and a beta of 1.21. Fortress Biotech has a 1 year low of $1.83 and a 1 year high of $4.53. The company has a current ratio of 2.86, a quick ratio of 2.77 and a debt-to-equity ratio of 0.18. The business has a fifty day simple moving average of $3.06 and a 200 day simple moving average of $2.95.
Institutional Investors Weigh In On Fortress Biotech
Analyst Upgrades and Downgrades
Several research analysts have weighed in on the company. Citigroup reaffirmed a “buy” rating on shares of Fortress Biotech in a research report on Monday, May 18th. Weiss Ratings reiterated a “sell (d)” rating on shares of Fortress Biotech in a report on Wednesday, July 8th. Finally, Wall Street Zen raised Fortress Biotech from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 24th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $17.00.
View Our Latest Report on FBIO
Fortress Biotech Company Profile
Fortress Biotech, Inc is a clinical‐stage biopharmaceutical company focused on acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Headquartered in New York, the company operates through a network of majority‐owned subsidiaries that target areas of high unmet medical need, including oncology, rare diseases and dermatology. Fortress Biotech’s business model emphasizes in‐licensing or acquiring promising drug candidates and coordinating their development through specialized affiliate companies, allowing for flexible capital allocation and focused management of individual programs.
Through its portfolio of subsidiaries, Fortress Biotech advances a diversified pipeline spanning small molecules, biologics and cell therapies.
Featured Stories
- Five stocks we like better than Fortress Biotech
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
